1Jaillard A, Cornu C, Durieux A, et al.Hemorrhagic transformation in acute ischemic stroke.The MAST-E study.MAST-E Group.Stroke,1999,30:1326-1332.
2Larrue V, von Kummer RR, Müller A, et al.Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).Stroke, 2001,32:438-441.
3Yong M, Kaste M.Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial.Stroke, 2008,39:366-372.
7Hlin6k Z1, Krejc[ I. Oxiraeetam prevents the MK-801 induced amnesia for the elevated plus-maze in mice J]. Behav Brain Res, 2000,117(1-2) :147-151.
8Cavoy A, Van Golf-Racht B, Delacour J. Relationships betweenarousal and cognition-enhancing effects of oxiracetam [J]. Pharmacol Biochem Behav, 1994,47 ( 2 ) :283-287.
9Hermida RC,Ayala DE,Portaluppi F. Circadian variation of bloo pressure :The basis for the chronotherapy of hyper- tension [J]. Advance Drug Deliviery Review,2007,59 (9- 10) :904--922.
